ViiV to trial twice-yearly HIV antibody dosing after Phase IIb success
The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
Clinical Trials Arena on MSN14h
MSD to push for approval of HIV combo after Phase III success
MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.
Researchers develop method to identify dormant cells that carry HIV
Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...
HIV's latent reservoir: New insights into Nef protein offer potential strategy to improve treatment
A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...
Managed Healthcare Executive6h
New Generation of Long-Acting Antiretrovirals Shows Promise
The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...
News-Medical.Net on MSN15h
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.
Sierra Sun Times13h
NIH Reports Tecovirimat is Safe But Ineffective as Treatment for Clade II Mpox
NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.